 A medical and menstrual history update, pregnancy test, HIV and sexually transmitted infections STI risk reduction counseling, and interview to assess behaviors toward vaginal gel use will occur during all study visits. HIVSTI counseling and testing, urinalysis, and blood collection will occur at study entry and at Week 24. Pelvic exam with colposcopy and vaginal swab collection will occur at study entry and Weeks 4, 12, and 24. For participants with chronic HBV, additional blood will be collected to monitor hepatitis B infection at study entry and Weeks 12, 24, 28, 32, and 36. 